High PARP-1 Expression is Associated with Tumor Invasion and Poor Prognosis in Gastric Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2016 Nov 30

PMID 27895737

Citations 35

Authors

Ying Liu

Yu Zhang

Ying Zhao

Dongna Gao

Jing Xing

Hui Liu

Affiliations

Soon will be listed here.

Abstract

Poly (adenosine diphosphate-ribose) polymerase 1 (PARP-1) was previously demonstrated to be overexpressed in numerous malignant tumors and associated with invasiveness and poor prognosis. However, the expression of the PARP-1 protein in gastric cancer and its association with clinical outcomes requires further investigation. In the present study, the expression of PARP-1 in 564 gastric cancer tissues and 335 tumor-adjacent control tissues is investigated, using tissue microarray-based immunohistochemistry. PARP-1 expression levels were demonstrated to be significantly higher in gastric cancer tissue samples, as compared with control tissue samples. In gastric cancer, high PARP-1 expression levels were significantly associated with infection (P=0.032), decreased differentiation (P<0.001), increased depth of invasion (P=0.037), presence of lymphatic invasion (P<0.001), presence of lymph node metastasis (P<0.001), and advanced tumor-node-metastasis (TNM) stage (P=0.015). High PARP-1 expression levels were associated with a significantly shorter overall survival rate (P<0.001) and disease-free survival rate (P=0.001) in patients with gastric cancer, particularly a subset of patients with infection or an advanced TNM stage. In addition, univariate analysis indicated that PARP-1 high expression levels were significantly associated with a poor prognosis in gastric cancer. These results suggest that PARP-1 expression may be involved in the progression and prognosis of gastric cancer, particularly -positive or advanced-stage gastric cancer.

Citing Articles

Roles of and Genes Expression in Cytogenetically Normal Acute Myeloid Leukemia.

Mahmoud H, Botros S, Fouad A, Kamel M, Abdel Aziz R Clin Med Insights Oncol. 2024; 18:11795549241295649.

PMID: 39497927 PMC: 11533204. DOI: 10.1177/11795549241295649.

Leveraging PARP-1/2 to Target Distant Metastasis.

Frederick M, Abdesselam D, Clouvel A, Croteau L, Hassan S Int J Mol Sci. 2024; 25(16).

PMID: 39201718 PMC: 11354653. DOI: 10.3390/ijms25169032.

PARP-1 selectively impairs -driven phenotypic and molecular features in intrahepatic cholangiocarcinoma.

Keggenhoff F, Castven D, Becker D, Stojkovic S, Castven J, Zimpel C Gut. 2024; 73(10):1712-1724.

PMID: 38857989 PMC: 11420749. DOI: 10.1136/gutjnl-2023-331237.

Disrupting Poly(ADP-ribosyl)ating Pathway Creates Premalignant Conditions in Mammalian Liver.

Karpova Y, Orlicky D, Schmidt E, Tulin A Int J Mol Sci. 2023; 24(24).

PMID: 38139034 PMC: 10743425. DOI: 10.3390/ijms242417205.

Studies on the mechanism of local and extra-intestinal tissue manifestations in AOM-DSS-induced carcinogenesis in BALB/c mice: role of PARP-1, NLRP3, and autophagy.

Singla S, Jena G Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(6):4321-4337.

PMID: 38091080 DOI: 10.1007/s00210-023-02878-8.

References

Li M, Threadgill M, Wang Y, Cai L, Lin X . Poly(ADP-ribose) polymerase inhibition down-regulates expression of metastasis-related genes in CT26 colon carcinoma cells. Pathobiology. 2009; 76(3):108-16. DOI: 10.1159/000209388. View

Hakme A, Wong H, Dantzer F, Schreiber V . The expanding field of poly(ADP-ribosyl)ation reactions. 'Protein Modifications: Beyond the Usual Suspects' Review Series. EMBO Rep. 2008; 9(11):1094-100. PMC: 2581850. DOI: 10.1038/embor.2008.191. View

Pu H, Horbinski C, Hensley P, Matuszak E, Atkinson T, Kyprianou N . PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis. Carcinogenesis. 2014; 35(11):2592-601. PMC: 4216059. DOI: 10.1093/carcin/bgu183. View

Goncalves A, Finetti P, Sabatier R, Gilabert M, Adelaide J, Borg J . Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat. 2010; 127(1):273-81. DOI: 10.1007/s10549-010-1199-y. View

Kim J, Pyun J, Cho S, Lee K, Kwack K . Lymph node metastasis of gastric cancer is associated with the interaction between poly (ADP-ribose) polymerase 1 and matrix metallopeptidase 2. DNA Cell Biol. 2011; 30(12):1011-7. DOI: 10.1089/dna.2011.1250. View

Donizy P, Pietrzyk G, Halon A, Kozyra C, Gansukh T, Lage H . Nuclear-cytoplasmic PARP-1 expression as an unfavorable prognostic marker in lymph node‑negative early breast cancer: 15-year follow-up. Oncol Rep. 2014; 31(4):1777-87. DOI: 10.3892/or.2014.3024. View

Weaver A, Yang E . Beyond DNA Repair: Additional Functions of PARP-1 in Cancer. Front Oncol. 2013; 3:290. PMC: 3841914. DOI: 10.3389/fonc.2013.00290. View

Brustmann H . Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. Int J Gynecol Pathol. 2007; 26(2):147-53. DOI: 10.1097/01.pgp.0000235064.93182.ec. View

FIELDING J, Roginski C, Ellis D, Jones B, Powell J, Waterhouse J . Clinicopathological staging of gastric cancer. Br J Surg. 1984; 71(9):677-80. DOI: 10.1002/bjs.1800710910. View

10.

Nossa C, Blanke S . Helicobacter pylori activation of PARP-1: usurping a versatile regulator of host cellular health. Gut Microbes. 2011; 1(6):373-8. PMC: 3056101. DOI: 10.4161/gmic.1.6.13572. View

11.

Hottiger M, Hassa P, Luscher B, Schuler H, Koch-Nolte F . Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci. 2010; 35(4):208-19. DOI: 10.1016/j.tibs.2009.12.003. View

12.

Chiou S, Jiang B, Yu Y, Chou S, Tsai P, Chang W . Poly(ADP-ribose) polymerase 1 regulates nuclear reprogramming and promotes iPSC generation without c-Myc. J Exp Med. 2013; 210(1):85-98. PMC: 3549716. DOI: 10.1084/jem.20121044. View

13.

Nossa C, Jain P, Tamilselvam B, Gupta V, Chen L, Schreiber V . Activation of the abundant nuclear factor poly(ADP-ribose) polymerase-1 by Helicobacter pylori. Proc Natl Acad Sci U S A. 2009; 106(47):19998-20003. PMC: 2785281. DOI: 10.1073/pnas.0906753106. View

14.

Lordick F, Allum W, Carneiro F, Mitry E, Tabernero J, Tan P . Unmet needs and challenges in gastric cancer: the way forward. Cancer Treat Rev. 2014; 40(6):692-700. DOI: 10.1016/j.ctrv.2014.03.002. View

15.

Atherton J . The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol. 2007; 1:63-96. DOI: 10.1146/annurev.pathol.1.110304.100125. View

16.

Staibano S, Pepe S, Lo Muzio L, Somma P, Mascolo M, Argenziano G . Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum Pathol. 2005; 36(7):724-31. DOI: 10.1016/j.humpath.2005.04.017. View

17.

Cepeda V, Fuertes M, Castilla J, Alonso C, Quevedo C, Soto M . Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy. Recent Pat Anticancer Drug Discov. 2008; 1(1):39-53. DOI: 10.2174/157489206775246430. View

18.

He W, Liu T, Shan Y, Zhu K, Li Y . PARP1 polymorphisms increase the risk of gastric cancer in a Chinese population. Mol Diagn Ther. 2012; 16(1):35-42. DOI: 10.1007/BF03256428. View

19.

Klauschen F, von Winterfeld M, Stenzinger A, Sinn B, Budczies J, Kamphues C . High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer. Histopathology. 2012; 61(3):409-16. DOI: 10.1111/j.1365-2559.2012.04225.x. View

20.

Nosho K, Yamamoto H, Mikami M, Taniguchi H, Takahashi T, Adachi Y . Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis. Eur J Cancer. 2006; 42(14):2374-81. DOI: 10.1016/j.ejca.2006.01.061. View